SXTP Stock Forecast & Price Target

60 Degrees is a specialty pharmaceutical company that is currently focused on developing and commercializing therapies for infectious diseases. The company's pipeline includes products for vector-borne, fungal, and viral diseases, including the Arakoda regimen of Tafenoquine and Celgosivir, as well as botanical extracts from Australian Chestnut Trees. However, the company's financial constraints and lack of visibility on ongoing clinical development plans have led to a downgrade in the rating to Neutral. While there is potential for the company to fill an unmet need in infectious disease, risks such as balance sheet and liquidity risks, regulatory approval risks, and potential dilution from future capital raises must be considered.

60 Degrees is expected to face a negative outlook due to its reported net loss of $2.2 million on sales of $0.2 million for Q1 FY26, lower product revenue, higher operating expenses, and share count variance. Despite high growth prospects, low visibility on regulatory approval for new indications and potential dilution from future capital raises remain risks. Clinical progress on tafenoquine for babesiosis will be a key pipeline catalyst, and the recent $2.5 million ATM raise will only provide cash for the next 3-6 months, suggesting the need for more financing in the near future.